Wonhee Lee
Family · Garden Grove, CANPI 1407338585
Payments from drug & device makers
Across 597 payments — averaging $22.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Nestle Healthcare Nutrition Inc.$1K
- Lilly USA, LLC$1K
- Amgen$1K
- Novo Nordisk$919
- Aimmune Therapeutics, Inc.$832
- plus $7K from 38 others
What the payments were for
- Travel & lodging$60%
- Food & beverage$13,18598%
- Education$2162%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,407 in reported general payments places this provider in the 95th percentile of 10,634 family providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 91 | $130,830 |
| ProliaDenosumab | 61 | $99,135 |
| VelphoroSucroferric Oxyhydroxide | 23 | $65,319 |
| TradjentaLinagliptin | 76 | $40,489 |
| OzempicSemaglutide | 30 | $38,429 |
| TrulicityDulaglutide | 33 | $33,428 |
| LinzessLinaclotide | 39 | $31,002 |
| GemtesaVibegron | 48 | $29,900 |
| VascepaIcosapent Ethyl | 72 | $27,613 |
| Evenity (2 Syringes)Romosozumab-Aqqg | 11 | $26,076 |
| JanuviaSitagliptin Phosphate | 34 | $22,805 |
| ZenpepLipase/Protease/Amylase | 17 | $22,633 |
| EliquisApixaban | 17 | $13,773 |
| RybelsusSemaglutide | 11 | $12,104 |
| JardianceEmpagliflozin | 11 | $10,772 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess | $1,316 | $161,832130 claims |
| AmgenProlia, Evenity (2 Syringes) | $1,026 | $125,21172 claims |
| Fresenius USA Marketing, Inc.Velphoro | $632 | $65,31923 claims |
| Boehringer IngelheimTradjenta, Jardiance | $491 | $51,26187 claims |
| Novo NordiskOzempic, Rybelsus | $919 | $50,53341 claims |
| Lilly USA, LLCTrulicity | $1,120 | $33,42833 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $80 | $29,90048 claims |
| MerckJanuvia | $28 | $22,80534 claims |
| Aimmune Therapeutics, Inc.Zenpep | $832 | $22,63317 claims |
| PfizerEliquis | $591 | $13,77317 claims |
| Astellas Pharma US IncMyrbetriq | $437 | $9,99719 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,634 family providers in California.
Other family in Garden Grove
- Lori RobertsonChino Hills$475K
- Annette ShonLos Angeles$406K
- Nancy GardettoSan Diego$394K
- Lisa HigginsHanford$311K
- Jennifer TougasBakersfield$302K
- Kim SchaferSacramento$288K
- Dawn MeyerSan Diego$270K
- Jennifer KangCerritos$255K
- Jenine StoneEscondido$231K
- Erin DwyerSan Diego$189K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.